Combination therapy with anti-PD-1 and anti-CTLA-4 drugs (durvalumab plus tremelimumab, NCT03753919 trial; nivolumab plus ipilimumab, NCT03246958 trial) is giving rise to great expectations in MTC. The gene discussed is PDCD1; the disease is medullary thyroid gland carcinoma.